Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo

Oxaliplatin is a very potent platinum(ii) drug which is frequently used in poly-chemotherapy schemes against advanced colorectal cancer. However, its benefit is limited by severe adverse effects as well as resistance development. Based on their higher tolerability, platinum(iv) prodrugs came into fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schueffl, Hemma, Theiner, Sarah, Hermann, Gerrit, Mayr, Josef, Fronik, Philipp, Groza, Diana, van Schonhooven, Sushilla, Galvez, Luis, Sommerfeld, Nadine S., Schintlmeister, Arno, Reipert, Siegfried, Wagner, Michael, Mader, Robert M., Koellensperger, Gunda, Keppler, Bernhard K., Berger, Walter, Kowol, Christian R., Legin, Anton, Heffeter, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494022/
https://www.ncbi.nlm.nih.gov/pubmed/34703544
http://dx.doi.org/10.1039/d1sc03311e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494022/
https://www.ncbi.nlm.nih.gov/pubmed/34703544
http://dx.doi.org/10.1039/d1sc03311e

Ejemplares similares